ESTROGENIC SUBSTANCE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ESTROGENIC SUBSTANCE (ESTROGENIC SUBSTANCE).
Estrogens bind to and activate nuclear estrogen receptors (ERα and ERβ), leading to gene transcription and regulation of reproductive tissues and secondary sexual characteristics.
| Metabolism | Estrogenic substances are metabolized primarily in the liver via hydroxylation (CYP3A4) and conjugation (glucuronidation and sulfation). Major metabolites include estrone, estradiol, and estriol, which undergo enterohepatic recirculation. |
| Excretion | Primarily renal as glucuronide and sulfate conjugates; approximately 60-80% excreted in urine, 10-30% in feces via biliary elimination. |
| Half-life | Terminal elimination half-life is approximately 13-27 hours for endogenous estrogens, with clinically therapeutically relevant metabolites having half-lives up to 24-36 hours, allowing once-daily dosing. |
| Protein binding | Approximately 97-99% bound to albumin and sex hormone-binding globulin (SHBG). |
| Volume of Distribution | Approximately 10-15 L/kg, indicating extensive tissue distribution, binding to estrogen receptors, and accumulation in fat stores. |
| Bioavailability | Oral: 5-10% due to extensive first-pass metabolism; intramuscular: 100% (given as esterified prodrug); transdermal: approximately 100% relative to IV, avoiding first-pass metabolism. |
| Onset of Action | Oral: 2-4 hours for clinical effects (e.g., estrogenic effects on vaginal epithelium); intramuscular: 1-2 days; transdermal: steady-state achieved within 2-6 hours after application. |
| Duration of Action | Oral: 24-48 hours; intramuscular: 3-7 days; transdermal: patch duration typically 7 days, with effects sustained as long as patch is worn. |
0.3 to 1.25 mg orally once daily; 25 to 100 mcg transdermal patch applied twice weekly; 0.5 to 2 mg vaginal cream daily for 3 weeks then 1 week off.
| Dosage form | INJECTABLE |
| Renal impairment | No specific dose adjustment recommended; use with caution in severe impairment due to potential fluid retention. |
| Liver impairment | Contraindicated in severe hepatic disease (Child-Pugh C); reduce dose by 50% in moderate impairment (Child-Pugh B). |
| Pediatric use | Not typically indicated for pediatric use; in rare cases for induction of puberty, starting dose 0.3 mg orally daily, titrated gradually. |
| Geriatric use | Initiate at lowest effective dose (0.3 mg orally daily or 25 mcg transdermal) to minimize thromboembolic and cardiovascular risks. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ESTROGENIC SUBSTANCE (ESTROGENIC SUBSTANCE).
| Breastfeeding | Excreted in breast milk; may suppress lactation. M/P ratio not established. Use during breastfeeding is not recommended due to potential adverse effects in nursing infants. |
| Teratogenic Risk | First trimester: Exposure associated with increased risk of congenital anomalies including cardiovascular defects and limb reduction defects. Second/third trimester: Potential for urogenital tract abnormalities in female offspring. Use contraindicated in pregnancy. |
| Fetal Monitoring |
■ FDA Black Box Warning
Estrogens should not be used to prevent cardiovascular disease or dementia. The Women's Health Initiative (WHI) substudies reported increased risks of myocardial infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein thrombosis in postmenopausal women (50-79 years) receiving conjugated estrogens (0.625 mg/day) with medroxyprogesterone acetate. The risk of dementia was also increased. Due to these risks, estrogens should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals.
| Serious Effects |
Undiagnosed abnormal genital bleeding, known or suspected breast cancer (except in appropriately selected patients), known or suspected estrogen-dependent neoplasia (e.g., endometrial cancer), active or history of venous thromboembolism (e.g., DVT, PE), active arterial thromboembolism (e.g., stroke, MI), known thrombophilic disorders (e.g., protein C, S, antithrombin deficiency), liver dysfunction or disease, hypersensitivity to any component, pregnancy, lactation (some formulations).
| Precautions | Cardiovascular disorders (increased risk of MI, stroke, VTE), malignant neoplasms (endometrial and breast cancer), dementia, gallbladder disease, hypercalcemia, visual abnormalities, hereditary angioedema, elevated blood pressure, hypertriglyceridemia, and impaired liver function. Should be discontinued if jaundice occurs. Not for use during pregnancy. |
Loading safety data…
| Monitor for signs of thromboembolism, hypertension, and hepatic dysfunction in mother. Fetal ultrasound for structural anomalies if inadvertent exposure occurs. |
| Fertility Effects | May inhibit ovulation and impair fertility during use. Effects are reversible upon discontinuation. Long-term use may affect menstrual cycle regularity. |